This site is intended for
U.S. healthcare professionals
COVERAGE AND ACCESS
Once you've made the decision to prescribe macitentan/tadalafil,
OPT for OPSYNVI®
One Pill, One Fill1
As a single-tablet combination of an ERA and a PDE5 inhibitor, OPSYNVI® can help you to avoid the added time and complexity of 2 separate prescriptions, so that you can focus on patients, not paperwork1
No Added Cost
Patients will pay no more for OPSYNVI® than they would for OPSUMIT® (macitentan) when both drugs are covered on the same formulary tier, allowing them to forgo any out-of-pocket cost of a separate PDE5 inhibitor prescription
Trial OPSYNVI®
A free trial offer is available for eligible patients to help them become familiar with OPSYNVI®. At the conclusion of the program, you and your patient decide whether to continue treatment.Subject to one (1) use per lifetime for the first supply of OPSYNVI®. Terms expire at the end of each calendar year and may change. This Voucher Program is open to patients who have commercial insurance, government coverage, or no insurance coverage; however, there is no guarantee of continuous accessibility after the program ends. See program requirements at JNJwithMe.com.
Science Liaison (MSL)Contact your MSL
ERA=endothelin receptor antagonist; PDE5i=phosphodiesterase type 5 inhibitor.
Reference: 1. OPSYNVI® (macitentan/tadalafil) full Prescribing Information. Actelion Pharmaceuticals US, Inc.